Behavioral Therapy Development for Methamphetamine Abusers

Behavioral Therapy Development for Methamphetamine Abuse

The purpose of this study is...to assess whether placing a substance abuse intervention for HIV+ methamphetamine users within an HIV medical care setting improves rates of follow-up on referral to treatment by primary care physicians; reduces drug use and sexual risk behaviors more than treatment-as-usual; and increases rates of adherence to HIV medication regimens.

Study Overview

• Status: Withdrawn
• Conditions: The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings
• Intervention / Treatment: Behavioral: Behavior Therapy

• Study Type: Interventional
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90024
      • UCLA Medical Center
    • Los Angeles, California, United States, 90035
      • UCLA CARE Clinic
    • Los Angeles, California, United States, 90024
      • UCLA, Integrated Substance Abuse Programs

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. HIV-seropositive, GBM receiving medical treatment for HIV for at least 30 days prior to signing informed consent at the UCLA CARE clinic, aged 18-65
2. Willing to give informed consent and comply with study procedures;
3. Willing to provide consent to contact treating physicians and pharmacies to assess adherence to HIV medications;
4. Diagnosed with current methamphetamine abuse as determined by MINI; and
5. Interested in seeking treatment for their methamphetamine abuse and in participating in this research project.

Exclusion Criteria:

1. Unwilling to give, or withdrawal of, informed consent;
2. Inability to understand nature of study;
3. A psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets DSM-IV-TR criteria for current bipolar disorder or a psychotic disorder);
4. Current suicidal ideation or suicide attempt within the past 3 months; and
5. Concurrent dependence on opiates, alcohol, or benzodiazepines as determined by MINI.
6. Total lack of any type of healthcare coverage. These potential participants will be given low-fee treatment referrals.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Craving
Medication compliance
Addiction severity
Psychiatric interview
Sex-risk behavior

Secondary Outcome Measures

Outcome Measure
Depression
Quality of Life

Collaborators and Investigators

• Sponsor: University of California, Los Angeles
• Collaborators: National Institute on Drug Abuse (NIDA)
• Investigators: Principal Investigator: James Peck, Other, University of California, Los Angeles

Study record dates

Study Major Dates

• Study Start (Anticipated): September 1, 2004
• Primary Completion (Actual): May 1, 2007
• Study Completion (Actual): May 1, 2007

Study Registration Dates

• First Submitted: November 3, 2005
• First Submitted That Met QC Criteria: November 3, 2005
• First Posted (Estimate): November 7, 2005

Study Record Updates

• Last Update Posted (Actual): February 17, 2020
• Last Update Submitted That Met QC Criteria: February 13, 2020
• Last Verified: February 1, 2020

More Information

Terms related to this study

• Keywords: Behavior Therapy; methamphetamine
• Other Study ID Numbers: NIDA-18075-1; R21DA018075 (U.S. NIH Grant/Contract); R21-18075-1